Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
1. Intra-Cellular Therapies shares surged 35% after Johnson & Johnson's acquisition announcement. 2. Johnson & Johnson will pay $132 per share, valuing Intra-Cellular at $14.6 billion. 3. ITCI's drug Caplyta had previously settled a patent lawsuit, boosting its stock. 4. The deal aims to enhance Johnson & Johnson's portfolio and growth prospects. 5. Expected regulatory approval for the acquisition by year-end; significant cash and debt funding.